CG Oncology (NASDAQ:CGON) versus MediWound (NASDAQ:MDWD) Head-To-Head Contrast

CG Oncology (NASDAQ:CGON) and MediWound (NASDAQ:MDWD) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Profitability

This table compares CG Oncology and MediWound’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
MediWound	-170.10%	-47.24%	-24.27%

Volatility and Risk

CG Oncology has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, MediWound has a beta of 0.09, suggesting that its stock price is 91% less volatile than the S&P 500.

Valuation & Earnings

This table compares CG Oncology and MediWound”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$6.23 million	922.12	-$160.99 million	($2.69)	-24.09
MediWound	$16.96 million	9.74	-$23.88 million	($1.80)	-7.14

MediWound has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 4.8% of CG Oncology shares are held by insiders. Comparatively, 9.2% of MediWound shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for CG Oncology and MediWound, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1	1	8	0	2.70
MediWound	1	1	4	0	2.50

CG Oncology currently has a consensus target price of $87.50, indicating a potential upside of 35.05%. MediWound has a consensus target price of $33.00, indicating a potential upside of 156.83%. Given MediWound’s higher possible upside, analysts clearly believe MediWound is more favorable than CG Oncology.

Summary

MediWound beats CG Oncology on 8 of the 14 factors compared between the two stocks.

About CG Oncology

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.